Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?

被引：75
|
作者：
Al-Khadairi, Ghaneya [1 ]
Decock, Julie [1 ,2 ]
机构：
[1] Qatar Fdn, HBKU, CHLS, POB 34110, Doha, Qatar
[2] Qatar Fdn, HBKU, QBRI, Canc Res Ctr, POB 34110, Doha, Qatar
来源：
CANCERS | 2019年 / 11卷 / 07期
关键词：
PRAME; cancer testis antigen; cancer vaccine; adoptive T cell therapy; immunotherapy; antibody; PREFERENTIALLY EXPRESSED ANTIGEN; LEUKEMIA-ASSOCIATED ANTIGENS; TUMOR-ASSOCIATED ANTIGENS; ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION; T-CELLS; CANCER/TESTIS ANTIGENS; EPIGENETIC REGULATION; POOR-PROGNOSIS; RETINOIC ACID;
D O I：
10.3390/cancers11070984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target.
引用
收藏
页数：14
相关论文
共 50 条
  • [1] Immunotherapy and immunoprevention of cancer: where do we stand?
    Cavallo, F
    Curcio, C
    Forni, G
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (05) : 717 - 726
  • [2] Immunotherapy in Gastrointestinal Cancer: Where Do We Stand?
    Tannapfel, Andrea
    Reinacher-Schick, Anke
    [J]. VISCERAL MEDICINE, 2019, 35 (01) : 1 - 2
  • [3] Immunotherapy in Head and Neck Cancer: Where Do We Stand?
    Natalia G. Vallianou
    Angelos Evangelopoulos
    Dimitris Kounatidis
    Fotis Panagopoulos
    Eleni Geladari
    Irene Karampela
    Theodora Stratigou
    Maria Dalamaga
    [J]. Current Oncology Reports, 2023, 25 : 897 - 912
  • [4] Immunotherapy in Head and Neck Cancer: Where Do We Stand?
    Vallianou, Natalia G.
    Evangelopoulos, Angelos
    Kounatidis, Dimitris
    Panagopoulos, Fotis
    Geladari, Eleni
    Karampela, Irene
    Stratigou, Theodora
    Dalamaga, Maria
    [J]. CURRENT ONCOLOGY REPORTS, 2023, 25 (08) : 897 - 912
  • [5] Targeting the Warburg Effect in Cancer: Where Do We Stand?
    Barba, Ignasi
    Carrillo-Bosch, Laura
    Seoane, Joan
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [6] Targeting Angiogenesis in Cancer Treatments: Where do we Stand?
    Petrovic, N.
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2016, 19 (02): : 226 - 238
  • [7] Local immunotherapy: where do we stand
    Passalacqua, G
    Canonica, GW
    [J]. REVUE FRANCAISE D ALLERGOLOGIE ET D IMMUNOLOGIE CLINIQUE, 1998, 38 (07): : 657 - 665
  • [8] Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?
    Peng, Yan
    Yan, Hongxiang
    Mei, Wuxuan
    Zhang, Pengfei
    Zeng, Changchun
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (10) : 1378 - 1391
  • [9] Combining Radiotherapy with Immunotherapy in Cervical Cancer: Where Do We Stand and Where Are We Going?
    Yan Peng
    Hongxiang Yan
    Wuxuan Mei
    Pengfei Zhang
    Changchun Zeng
    [J]. Current Treatment Options in Oncology, 2023, 24 : 1378 - 1391
  • [10] Targeting SSX cancer–testis antigens for immunotherapy
    Annette Fenner
    [J]. Nature Reviews Urology, 2011, 8 (12) : 647 - 647
12345